Mouse IL13RA2 / CD213A2 (His Tag) recombinant protein

Cat.#: 503676

Size:

Special Price 621.5 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Mouse IL13RA2 / CD213A2 (His Tag) recombinant protein
  • Documents
  • Description
    Interleukin-13 receptor subunit alpha-2 (IL13RA2/IL-13RA2) is also known as also known as cluster of differentiation 213A2 (CD213A2), IL-13 receptor subunit alpha-2, IL-13R subunit alpha-2, and IL-13RA2. The IL13RA2 is often overexpressed in brain tumors, making Il13ra2 one of the vaccine targets for immunotherapy of glioma. IL13RA2/IL-13RA2 is a cancer-associated receptor that is present in greater than 80% of High Grade Astrocytomas (HGA) and has recently been recognized as a cytokine that predisposes breast cancer cells to metastasize. Expression of IL13Rα2 was rapidly lost from the surface of transduced cells grown in culture. The loss appeared to be related to ligands present in fetal bovine serum in the medium. None of the malignant glioma cell lines cultivated in vitro and tested to date exhibited the IL13Rα2 receptor. A recombinant virus (R5111) enters cells via its interaction with the IL13Rα2 receptor in a manner that cannot be differentiated from the interaction of wild-type virus with its receptors.
  • Protein name
    Interleukin-13 receptor subunit alpha-2
  • Protein short names
    IL-13R; IL13RA2; IL13BP; CT19; CD213A2
  • Uniprot ID
    O88786
  • Gene Name
    Il13ra2
  • Source/Expression Host
    Human Cells
  • Expression Plasmid/cDNA
    A DNA sequence encoding the extracellular domain (Met 1-Lys 334) of mouse IL13R?2 (NP_032382.1) precursor was fused with a polyhistidine tag at the C-terminus.
  • Protein Species
    Mouse
  • Molecular weight
    The recombinant mouse IL13R?2 consists of 324 amino acids after removal of the signal peptide and has a predicted molecular mass of 38 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rmIL13R?2 is approximately 45-50 kDa due to glycosylation.
  • Purity
    > 98 % as determined by SDS-PAGE
  • Activity
    Measured by its ability to inhibit IL13 dependent proliferation of TF1 human erythroleukemic cells. Kitamura, T. et al. (1989) J. Cell Physiol. 140: 323. The ED50 for this effect is typically 0.1-0.5 μg/mL.
  • Validations

    Mouse IL13RA2 / CD213A2 Protein (His Tag) SDS-PAGE

    Mouse IL13RA2 / CD213A2 Protein (His Tag) SDS-PAGE

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"